Drug
Part 1 Lou064
Part 1 Lou064: highest development phase Phase 1, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Part 1; LOU064 (Remibrutinib) NCT05753592 | Phase 1 | Hepatic Impairment |
Latest
No recent events.
Follow Part 1 Lou064 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.